F. B. Oldham

1.5k citations

31 papers · 939 indexed · h-index 15

Hematology top 5%
- Hematopoietic Stem Cell Transplantation 6
Biomaterials top 5%
Oncology top 10%
- Cancer Treatment and Pharmacology 13
- Colorectal Cancer Treatments and Studies 6
- Lung Cancer Research Studies 5
- Neutropenia and Cancer Infections 4
Genetics top 10%
Immunology
- Immunotherapy and Immune Responses 3
Pulmonary and Respiratory Medicine
- Lung Cancer Treatments and Mutations 13
Hepatology
- Hepatocellular Carcinoma Treatment and Prognosis 4

Co-authors: Jack W. Singer Stewart D. Chipman Gabriella Pezzoni Amy J. Eisenfeld B. Bandstra Mary O’Brien D. Van Epps DE Williams
Cited by: Hematology Biomaterials Oncology
Journals: Journal of Clinical Oncology (11 papers)Journal of Thoracic Oncology (5 papers)Blood (2 papers)
Partner nations: United States United Kingdom Ireland

In The Last Decade

F. B. Oldham

31 papers receiving 905 citations

Peers

Countries citing papers authored by F. B. Oldham

Since Specialization

Citations

This map shows the geographic impact of F. B. Oldham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. B. Oldham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. B. Oldham more than expected).

Fields of papers citing papers by F. B. Oldham

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. B. Oldham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. B. Oldham. The network helps show where F. B. Oldham may publish in the future.

Co-authorship network

The 25 scholars most cited alongside F. B. Oldham, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with F. B. Oldham Line = papers co-authored together F. B. Oldham links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Performans Statusu 2 Olan ve İleri Evre Küçük Hücreli Dışı Akciğer Kanseri Olgularında Kombinasyona Karşı Tek Ajan Kemoterapisi İki Büyük Randomize Klinik Çalışma Çerçevesinde Prognostik Faktörler ve Tedavi Seçimi Journal of Thoracic Oncology ·Rogério Lilenbaum,Victoria Villaflor,Corey J. Langer,Kenneth J. O’Byrne,Gani Muhammad Ramadlan,Helen J. Ross,Mark A. Socinski,F. B. Oldham,Kees Jansen,Jack W. Singer,Philip Bonomi	2009	1
2	Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: Prognostic Factors and Treatment Selection Based on Two Large Randomized Clinical Trials Journal of Thoracic Oncology ·Rogério Lilenbaum,Victoria Villaflor,Corey J. Langer,Kenneth J. O’Byrne,Mary O’Brien,Helen J. Ross,Mark A. Socinski,F. B. Oldham,Kees Jansen,Jack W. Singer,Philip Bonomi	2009	2
3	Randomized Phase III Trial Comparing Single-Agent Paclitaxel Poliglumex (CT-2103, PPX) with Single-Agent Gemcitabine or Vinorelbine for the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer Journal of Thoracic Oncology ·Mary O’Brien,Mark A. Socinski,อัครพล สามารถ,Igor Bondarenko,Antoaneta Tomova,Rose Naluyima,Yevhen Hotko,戴凌,Sylwester Latkowski,Amy J. Eisenfeld,Larissa Sandalic,F. B. Oldham,B. Bandstra,Alan B. Sandler,Jack W. Singer	2008	96
4	Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer British Journal of Cancer ·Luis Paz‐Ares,Helen J. Ross,Mary O’Brien,A. Riviére,U. Gatzemeier,Joachim von Pawel,E. Kaukel,L Freitag,W. Digel,Helge Bischoff,Rosario García‐Campelo,Nicholas Iannotti,Pavel Reiterer,Isabel Bover,J Prendiville,Amy J. Eisenfeld,F. B. Oldham,B. Bandstra,Jack W. Singer,Philip Bonomi	2008	125
5	Phase III Trial Comparing Paclitaxel Poliglumex (CT-2103, PPX) in Combination with Carboplatin Versus Standard Paclitaxel and Carboplatin in the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer Journal of Thoracic Oncology ·Corey J. Langer,Kenneth J. O’Byrne,Mark A. Socinski,陈玉雯,Krzysztof Leśniewski-Kmak,Martin Šmakal,Tudor–Eliade Ciuleanu,Sergey Orlov,Mircea Dediu,David F. Heigener,Amy J. Eisenfeld,Larissa Sandalic,F. B. Oldham,Jack W. Singer,Helen J. Ross	2008	4
6	A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors Cancer Chemotherapy and Pharmacology ·Claire F. Verschraegen,Keith M. Skubitz,Adil Daud,Andrzej P. Kudelka,Ian Rabinowitz,Cecilia Allievi,Amy J. Eisenfeld,Jack W. Singer,F. B. Oldham	2008	29
7	B2-04: Single agent versus combination therapy in advanced NSCLC patients with performance status 2: Results from a regression analysis of STELLAR 3 and 4 Journal of Thoracic Oncology ·Rogério Lilenbaum,B. Bandstra,Corey J. Langer,Kenneth J. O’Byrne,Mary O’Brien,Helen J. Ross,Mark A. Socinski,F. B. Oldham,Jack W. Singer,Philip Bonomi	2007	2
8	Medical resource utilization (MRU) and costs associated with paclitaxel poliglumex (PPX) compared to gemcitabine (Gem) or vinorelbine (Vin) in non-small cell lung cancer (NSCLC) patients Journal of Clinical Oncology ·F. B. Oldham,Kathryn Anastassopoulos,Kenneth J. O’Byrne,P. Meriaudeau,Caroline Schaefer	2007	1
9	Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer?drug conjugate International Journal of Nanomedicine ·Stewart D. Chipman,F. B. Oldham,Gabriella Pezzoni,Jack W. Singer	2006	96
10	Phase I Study of CT-2103, A Polymer-Conjugated Paclitaxel, and Carboplatin in Patients with Advanced Solid Tumors Cancer Investigation ·John Nemunaitis,Casey Cunningham,Neil Senzer,Megan M. Gray,F. B. Oldham,John Pippen,Robert Mennel,Amy J. Eisenfeld	2005	32
11	Efficacy and Safety of Paclitaxel Poliglumex as First-Line Chemotherapy in Patients at High Risk with Advanced-Stage Non–Small-Cell Lung Cancer: Results of a Phase II Study Clinical Lung Cancer ·Donald Richards,Paul Richards,David Bodkin,Marcus A. Neubauer,F. B. Oldham	2005	23
12	A phase I study of paclitaxel poliglumex (PPX) in combination with cisplatin (CIS) for patients (pts) with advanced cancer Journal of Clinical Oncology ·Keith M. Skubitz,Claire F. Verschraegen,Adil Daud,A. Bernareggi,F. B. Oldham	2005	2
13	Phase I Trial of Interferon gamma Retroviral Vector Administered Intratumorally with Multiple Courses in Patients with Metastatic Melanoma Human Gene Therapy ·John Nemunaitis,Timothy Fong,Francis Burrows,久志大槻,Xuejuan Cheng,Bengüsü Hazal Abacıoğlu,Wally Meyer,Dee Wynne,Edwin D. Ibañez,John Pippen,F. B. Oldham,Dale Ando	1999	39
14	Rapid engraftment after allogeneic transplantation using CD34-enriched marrow cells Bone Marrow Transplantation ·Kenneth Cornetta,LoisA. Abbott,Behrooz Goleyn,Robert Hromas,Rafat Abonour,Associação Brasileira de Psiquiatria,Bizsel Kc,Kazuyuki Hatake,Thomazine Forsander Johansson,Constance Danielson,R Gonin,Caroline Trolez,F. B. Oldham,EF Srour	1998	15
15	Highly purified CD34-positive cells reconstitute hematopoiesis. Journal of Clinical Oncology ·Curt I. Civin,Thomas M. Trischmann,Nina S. Kadan‐Lottick,John M. Davis,Stephen J. Noga,Kenneth J. Cohen,V. K. Mikheyev,Norihiko Akano,Joseph M. Wiley,Ping‐Yee Law,A Hardwick,F. B. Oldham,Adrian P. Gee	1996	116
16	Changes in blood counts after the administration of granulocyte‐colony‐ stimulating factor and the collection of peripheral blood stem cells from healthy donors Transfusion ·David F. Stroncek,Mary Clay,Judith A. Smith,Sarah J. Ilstrup,F. B. Oldham,Jeffrey McCullough	1996	36
17	Selection and expansion of peripheral blood CD34+ cells in autologous stem cell transplantation for breast cancer Blood ·SF Williams,Gabriela Nemecek,JG Bender,C D Buller,Mollie Elspeth MacGregor,E. Fuja,Chang Wu Yu,M Schilling,SL Smith,DE Williams,F. B. Oldham,D. Van Epps	1996	152
18	Clinical Use of Selected and Expanded Peripheral Blood CD34+ Cells: A Preliminary Report of Feasibility and Safety Journal of Hematotherapy ·Todd M. Zimmerman,Stephanie Williams,Shizue Oyama,Kenneth A. Egol,E. Fuja,Chang Wu Yu,Mollie Elspeth MacGregor,Stephen J Smith,M Schilling,F. B. Oldham,宣勝今村,Haskell John	1995	5
19	Dosing regimen of granulocyte-macrophage colony-stimulating factor to support dose-intensive chemotherapy. Journal of Clinical Oncology ·James A. Neidhart,A Mangalik,Christine A. Stidley,A. Rajasehkara Reddy,Zoia Runovska,Diana Lynn Cook,Dagmar Oette,F. B. Oldham	1992	45
20	Phase I-II trial of high-dose epirubicin in patients with lymphoma. PubMed ·Delvyn C. Case,Richard A. Gams,Thomas J. Ervin,Adrian Silaghi,F. B. Oldham	1987	20

About F. B. Oldham

F. B. Oldham is a scholar working on Oncology, Hematology, Hepatology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 31 papers that have together received 939 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (13 papers), Lung Cancer Treatments and Mutations (13 papers), Colorectal Cancer Treatments and Studies (6 papers), Hematopoietic Stem Cell Transplantation (6 papers), Lung Cancer Research Studies (5 papers), Hepatocellular Carcinoma Treatment and Prognosis (4 papers), Neutropenia and Cancer Infections (4 papers) and Immunotherapy and Immune Responses (3 papers). The work is most often cited by research in Hematology (300 citations), Biomaterials (253 citations), Oncology (397 citations), Genetics (112 citations) and Immunology (106 citations). F. B. Oldham has collaborated with scholars based in United States, United Kingdom and Ireland. Frequent co-authors include Jack W. Singer, Stewart D. Chipman, Gabriella Pezzoni, Amy J. Eisenfeld, B. Bandstra, Mary O’Brien, D. Van Epps, DE Williams, JG Bender and M Schilling. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Blood, Human Gene Therapy and British Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact